CA2252225A1 - Utilisation d'un element sensible a rev modifie (rre) dans des procedes et compositions servant a lutter contre l'infection par le vih - Google Patents

Utilisation d'un element sensible a rev modifie (rre) dans des procedes et compositions servant a lutter contre l'infection par le vih Download PDF

Info

Publication number
CA2252225A1
CA2252225A1 CA002252225A CA2252225A CA2252225A1 CA 2252225 A1 CA2252225 A1 CA 2252225A1 CA 002252225 A CA002252225 A CA 002252225A CA 2252225 A CA2252225 A CA 2252225A CA 2252225 A1 CA2252225 A1 CA 2252225A1
Authority
CA
Canada
Prior art keywords
nucleic acid
rev
hiv
binding
rre
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002252225A
Other languages
English (en)
Inventor
Jonathan Karn
Rodney Warren Zemmel
Peter Jonathan Gasking Butler
Roger Kingdon Craig
Alistair Simpson Irvine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis Cambridge Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9607819.1A external-priority patent/GB9607819D0/en
Application filed by Individual filed Critical Individual
Publication of CA2252225A1 publication Critical patent/CA2252225A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne un acide nucléique isolé qui comprend deux sites de liaison liés de manière opérationnelle et destinés à la protéine Rev du VIH. Ces sites comprennent un motif de nucléation et un motif d'oligomérisation. L'acide nucléique lie des monomères de ladite protéine Rev avec davantage de coopérativité qu'un RRE de type sauvage.
CA002252225A 1996-04-15 1997-04-15 Utilisation d'un element sensible a rev modifie (rre) dans des procedes et compositions servant a lutter contre l'infection par le vih Abandoned CA2252225A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9607819.1 1996-04-15
GBGB9607819.1A GB9607819D0 (en) 1996-04-15 1996-04-15 Anti-hiv agents
US1726896P 1996-05-13 1996-05-13
US60/017,268 1996-05-13

Publications (1)

Publication Number Publication Date
CA2252225A1 true CA2252225A1 (fr) 1997-10-23

Family

ID=26309134

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002252225A Abandoned CA2252225A1 (fr) 1996-04-15 1997-04-15 Utilisation d'un element sensible a rev modifie (rre) dans des procedes et compositions servant a lutter contre l'infection par le vih

Country Status (5)

Country Link
EP (1) EP0914443A2 (fr)
JP (1) JP2001517074A (fr)
AU (1) AU2572097A (fr)
CA (1) CA2252225A1 (fr)
WO (1) WO1997039128A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2493300A (en) * 1999-01-06 2000-07-24 Regents Of The University Of California, The Modulation of hiv replication using sam68
GB0719367D0 (en) * 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020541D0 (en) * 1990-09-20 1990-10-31 Medical Res Council Viral growth inhibition

Also Published As

Publication number Publication date
JP2001517074A (ja) 2001-10-02
AU2572097A (en) 1997-11-07
EP0914443A2 (fr) 1999-05-12
WO1997039128A3 (fr) 1998-11-12
WO1997039128A2 (fr) 1997-10-23

Similar Documents

Publication Publication Date Title
Churcher et al. High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region
Chen et al. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes
Sullenger et al. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation
Chatterjee et al. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector
Feinberg et al. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation.
US6107062A (en) Antisense viruses and antisense-ribozyme viruses
Pearson et al. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.
Carroll et al. Identification of lentivirus tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus type 1 tat gene chimeras
US5736294A (en) Reagents and methods for modulating gene expression through RNA mimicry
US6225045B1 (en) Assays for screening for inhibitors of HIV
Kashanchi et al. Involvement of transcription factor YB-1 in human T-cell lymphotropic virus type I basal gene expression
Najera et al. Synergistic stimulation of HIV-1 rev-dependent export of unspliced mRNA to the cytoplasm by hnRNP A1
WO1998047913A2 (fr) Inhibition d'une replication du vih-1 par un analogue peptidique tat du domaine de fixation d'arn
US5985661A (en) Anti-HIV ribozymes
Wu et al. Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition
AU696399B2 (en) Delivery system controlled through factors associated with HIV and cell
NO319376B1 (no) Ribozymer som malsoker retrovirale pakkende sekvensekresjons-konstruksjoner, transfer vektor, celle innbefattende en ribozymsekvens, human celle resistent mot HIV-infeksjon, og en farmasoytisk sammensetning.
Lee et al. Multiple positive and negative cis-acting elements that mediate transactivation by bel1 in the long terminal repeat of human foamy virus
Rhim et al. Exon2 of HIV-2 Tat contributes to transactivation of the HIV-2 LTR by increasing binding affinity to HIV-2 TAR RNA
Han et al. Transaction of heterologous promoters by HIV–1 tat
US6776986B1 (en) Inhibition of HIV-1 replication by antisense RNA expression
Fraisier et al. Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins
Ventura et al. Ribozyme targeting of HIV-1 LTR
CA2252225A1 (fr) Utilisation d'un element sensible a rev modifie (rre) dans des procedes et compositions servant a lutter contre l'infection par le vih
AU717233B2 (en) Inhibition of HIV-1 replication by antisense RNA expression

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead